In alternative embodiments, the invention provides compositions and methods for identifying individuals that would be responsive to a treatment comprising (including) blocking activation of integrin polypeptide alphav-beta3 (or αv-β3), or blocking the interaction of a ligand with integrin polypeptide alphav-beta3 (or αv-β3). The invention provides compositions and methods for determining the effectiveness of such a treatment and can contribute to a prognosis for the patient.
